GLGilles Leboucher

Gilles Leboucher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gilles Leboucher has a total of 202 co-authors. Here are the top co-authors by number of shared publications:

  • Tristan Ferry

    Infectious and Tropical Diseases Unit, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France

    7 shared publications
  • Bruno Charpiat

    5 shared publications
  • Anne-Lise Bienvenu

    Service de Pharmacie, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France; Univ Lyon, Malaria Research Unit, SMITh, ICBMS UMR 5246, Lyon, France

    4 shared publications
  • Bruno Charpiat

    Pharmacie du groupement hospitalier Nord, hospices civils de Lyon, 103, grande rue de la Croix-Rousse, 69317 Lyon, France

    4 shared publications
  • Florent Valour

    Reference center for the management of complex bone and joint infection (CRIOAc Lyon, www.crioac-lyon.fr), Hospices Civils de Lyon, Lyon, France; Department of infectious diseases, Hospices Civils de Lyon, Lyon, France; CIRI - Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Univ Lyon, Lyon, France

    4 shared publications
  • B. Allenet

    3 shared publications

Latest Publications

  • Open Access

    Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia

    by Cécile Teney, Jean-Charles Poupelin, Thomas Briot, Myrtille Le Bouar, Cindy Fevre, Sophie Brosset, Olivier Martin, Florent Valour, Tiphaine Roussel-Gaillard, Gilles Leboucher, et al.

    Pseudomonas aeruginosa is one of the main causes of healthcare-associated infection in Europe that increases patient morbidity and mortality. Multi-resistant pathogens are a major public health issue in burn centers. Mortality increases when the initial antibiotic treatment is inappropriate, especially if the patient is infected with P. aeruginosa strains that are resistant to many antibiotics. Phage therapy is an emerging option to treat severe P. aeruginosa infections. It involves using natural viruses called bacteriophages, which have the ability to infect, replicate, and, theoretically, destroy the P. aeruginosa population in an infected patient. We report here the case of a severely burned patient who experienced relapsing ventilator-associated pneumonia associated with skin graft infection and bacteremia due to extensively drug-resistant P. aeruginosa. The patient was successfully treated with personalized nebulized and intravenous phage therapy in combination with immunostimulation (interferon-γ) and last-resort antimicrobial therapy (imipenem-relebactam).


  • Top Cited Papers
    Open Access

    Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection

    by T. Ferry, C. Kolenda, F. Laurent, G. Leboucher, M. Merabischvilli, S. Djebara, C.-A. Gustave, T. Perpoint, C. Barrey, J.-P. Pirnay, et al.

    Bone and joint infections (BJI) are one of the most difficult-to-treat bacterial infection, especially in the era of antimicrobial resistance. Lytic bacteriophages (phages for short) are natural viruses that can selectively target and kill bacteria. They are considered to have a high therapeutic potential for the treatment of severe bacterial infections and especially BJI, as they also target biofilms. Here we report on the management of a patient with a pandrug-resistant Pseudomonas aeruginosa spinal abscess who was treated with surgery and a personalized combination of phage therapy that was added to antibiotics. As the infecting P. aeruginosa strain was resistant to the phages developed by private companies that were contacted, we set up a unique European academic collaboration to find, produce and administer a personalized phage cocktail to the patient in due time. After two surgeries, despite bacterial persistence with expression of small colony variants, the patient healed with local and intravenous injections of purified phages as adjuvant therapy.


  • Open Access

    Personalized bacteriophage therapy to treat pandrug-resistant spinal P. aeruginosa infection

    by Tristan Ferry, Camille Kolenda, Frederic Laurent, Gilles Leboucher, Maya Merabischvilli, Sarah Djebara, Claude-Alexandre Gustave, Thomas Perpoint, Cédric Barrey, Jean-Paul Pirnay, et al.

    A pandrug-resistant P. aeruginosa spinal abscess was treated with surgery and personalized phage therapy that was added to cefiderocol and colistin. After a 2-stage approach, despite bacterial persistence with expression of small colony variants, the patient cured with local and intravenous injections of purified bacteriophages as part of the treatment.

  • Open Access

    Past and Future of Phage Therapy and Phage-Derived Proteins in Patients with Bone and Joint Infection

    by Tristan Ferry, Camille Kolenda, Thomas Briot, Aubin Souche, Sébastien Lustig, Jérôme Josse, Cécile Batailler, Fabrice Pirot, Mathieu Medina, Gilles Leboucher, et al.

    Phage-derived therapies comprise phage therapy and the use of phage-derived proteins as anti-bacterial therapy. Bacteriophages are natural viruses that target specific bacteria. They were proposed to be used to treat bacterial infections in the 1920s, before the discovery and widespread over-commercialized use of antibiotics. Phage therapy was totally abandoned in Western countries, whereas it is still used in Poland, Georgia and Russia. We review here the history of phage therapy by focusing on bone and joint infection, and on the development of phage therapy in France in this indication. We discuss the rationale of its use in bacterial infection and show the feasibility of phage therapy in the 2020s, based on several patients with complex bone and joint infection who recently received phages as compassionate therapy. Although the status of phage therapy remains to be clarified by health care authorities, obtaining pharmaceutical-grade therapeutic phages (i.e., following good manufacturing practice guidelines or being “GMP-like”) targeting bacterial species of concern is essential. Moreover, multidisciplinary clinical expertise has to determine what could be the relevant indications to perform clinical trials. Finally “phage therapy 2.0” has to integrate the following steps: (i) follow the status of phage therapy, that is not settled and defined; (ii) develop in each country a close relationship with the national health care authority; (iii) develop industrial–academic partnerships; (iv) create academic reference centers; (v) identify relevant clinical indications; (vi) use GMP/GMP-like phages with guaranteed quality bioproduction; (vii) start as salvage therapy; (vii) combine with antibiotics and adequate surgery; and (viii) perform clinical trials, to finally (ix) demonstrate in which clinical settings phage therapy provides benefit. Phage-derived proteins such as peptidoglycan hydrolases, polysaccharide depolymerases or lysins are enzymes that also have anti-biofilm activity. In contrast to phages, their development has to follow the classical process of medicinal products. Phage therapy and phage-derived products also have a huge potential to treat biofilm-associated bacterial diseases, and this is of crucial importance in the worldwide spread of antimicrobial resistance.


  • Open Access

    Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients

    by Anne-Lise Bienvenu, Pierre Pradat, Alexandra Plesa, Vincent Leclerc, Vincent Piriou, Jean-Luc Fellahi, Laurent Argaud, Thomas Rimmelé, Jean Menotti, Frédéric Aubrun, et al.

    Therapeutic drug monitoring (TDM) is essential for voriconazole to ensure optimal drug exposure, mainly in critically ill patients for whom voriconazole demonstrated a large variability. The study aimed at describing factors associated with trough voriconazole concentrations in critically ill patients and evaluating the impact of voriconazole concentrations on adverse effects. A 2-year retrospective multicenter cohort study (NCT04502771) was conducted in six intensive care units. Adult patients who had at least one voriconazole TDM were included. Univariable and multivariable linear regression analyses were performed to identify predictors of voriconazole concentrations, and univariable logistic regression analysis, to study the relationship between voriconazole concentrations and adverse effects. During the 2-year study period, 70 patients were included. Optimal trough voriconazole concentrations were reported in 37 patients (52.8%), subtherapeutic in 20 (28.6%), and supratherapeutic in 13 (18.6%). Adverse effects were reported in six (8.6%) patients. SOFA score was identified as a factor associated with an increase in voriconazole concentration (p = 0.025), mainly in the group of patients who had SOFA score ≥ 10. Moreover, an increase in voriconazole concentration was shown to be a risk factor for occurrence of adverse effects (p = 0.011). In that respect, critically ill patients who received voriconazole treatment must benefit from a TDM, particularly if they have a SOFA score ≥ 10. Indeed, identifying patients who are overdosed will help to prevent voriconazole related adverse effects. This result is of utmost importance given the recognized COVID-19-associated pulmonary aspergillosis in ICU patients for whom voriconazole is among the recommended first-line treatment.


  • Open Access

    Metapopulation ecology links antibiotic resistance, consumption, and patient transfers in a network of hospital wards

    by Julie Teresa Shapiro, Gilles Leboucher, Anne-Florence Myard-Dury, Pascale Girardo, Anatole Luzzati, Mélissa Mary, Jean-François Sauzon, Bénédicte Lafay, Olivier Dauwalder, Frédéric Laurent, et al.

    Antimicrobial resistance (AMR) is a global threat. A better understanding of how antibiotic use and between-ward patient transfers (or connectivity) impact population-level AMR in hospital networks can help optimize antibiotic stewardship and infection control strategies. Here, we used a metapopulation framework to explain variations in the incidence of infections caused by seven major bacterial species and their drug-resistant variants in a network of 357 hospital wards. We found that ward-level antibiotic consumption volume had a stronger influence on the incidence of the more resistant pathogens, while connectivity had the most influence on hospital-endemic species and carbapenem-resistant pathogens. Piperacillin-tazobactam consumption was the strongest predictor of the cumulative incidence of infections resistant to empirical sepsis therapy. Our data provide evidence that both antibiotic use and connectivity measurably influence hospital AMR. Finally, we provide a ranking of key antibiotics by their estimated population-level impact on AMR that might help inform antimicrobial stewardship strategies.


  • Open Access

    Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis

    by Anne-Lise Bienvenu, Pierre Pradat, Claude Guerin, Frederic Aubrun, Jean-Luc Fellahi, Arnaud Friggeri, Céline Guichon, Romain Hernu, Jean Menotti, Céline Monard, et al.


  • Open Access

    Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria

    by Yobouet Ines Kouakou, Michel Tod, Gilles Leboucher, Adeline Lavoignat, Guillaume Bonnot, Anne-Lise Bienvenu, Stephane Picot